AI assistant
Celldex Therapeutics, Inc. — Director's Dealing 2008
Mar 11, 2008
31801_dirs_2008-03-11_c4834df8-2c1c-41f5-a4a8-ab68212ef375.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AVANT IMMUNOTHERAPEUTICS INC (AVAN)
CIK: 0000744218
Period of Report: 2008-03-07
Reporting Person: MARSH HENRY C JR (V.P. Research)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2008-03-07 | Incentive Stock Option | $8.16 | A | 41666 | Acquired | 2015-03-07 | Common Stock (41666) | Direct |
| 2008-03-07 | Incentive Stock Option | $20.06 | M | 1250 | Acquired | 2008-12-09 | Common Stock (1250) | Direct |
Footnotes
F1: This option was granted for 500,000 shares at an exercise price of $0.68 per share, but was adjusted to reflect the one-for-twelve reverse stock split that occurred on March 7, 2008.
F2: 25% of the shares vest annually over the first four years.
F3: 101,000 options granted under the AVANT 1999 Stock Option and Incentive Plan were cancelled according to their terms for no consideration on March 7, 2008.
F4: This option was previously reported as covering 15,000 shares at an exercise price of $1.672 per share, but was adjusted to reflect the one-for-twelve reverse stock split that occurred onmarch 7, 2008.